title: Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome.
abstract: Intravenous immunoglobulin (IVIG) has emerged as a promising treatment that interrupts the progression of Stevens-Johnson syndrome (SJS). Our patient experienced an uncommon adverse effect, non-eczematous, vesiculobullous eruptions, after treatment with IVIG. These new lesions developed rapidly on the palms while most previous SJS bullous lesions subsided. A skin biopsy of these new lesions showed an intracorneal vesicle, without epidermal necrosis, with inflammatory cell infiltration. IVIG-induced, vesiculobullous eruptions are discussed, along with their possible pathogenesis. With the increasing use of IVIG for treatment of bullous dermatoses, recognition of this rare adverse effect is important for prompt differential diagnosis.
authors: Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.
authors: Wan-Lung
authors: WL
authors: Lin
authors: Wen-Chi
authors: WC
authors: Lin
authors: Ya-Ching
authors: YC
authors: Chang
authors: Li-Cheng
authors: LC
authors: Yang
authors: Shuen-Iu
authors: SI
authors: Hung
authors: Hong-Shang
authors: HS
authors: Hong
authors: Wen-Hung
authors: WH
authors: Chung
mesh_terms: D001706:Biopsy; D003937:Diagnosis, Differential; D005260:Female; D006229:Hand Dermatoses / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000175:diagnosis; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors